|Table of Contents|

Expression of CD24 in triple negative breast cancer and its relationship with EMT

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
217-221
Research Field:
Publishing date:

Info

Title:
Expression of CD24 in triple negative breast cancer and its relationship with EMT
Author(s):
PU Lulan1; WANG Dongsheng2; ZHOU Yuqing1; FANG Lingyu1; CHEN Yanru1; CHEN Maoshan3; DENG Shishan1; HOU Lingmi4
1.School of Basic Medicine and Forensic Medicine,North Sichuan Medical College,Sichuan Nanchong 637000,China;2.Laboratory Department of Sichuan Cancer Hospital,Sichuan Chengdu 610000,China;3.Department of Thyroid and Breast Surgery,Suining Central Hospital,Sichuan Suining 629000,China;4.Department of Thyroid and Breast Surgery,Affiliated Hospital of North Sichuan Medical College,Sichuan Nanchong 637000,China.
Keywords:
CD24; triple negative breast cancer; migration; EMT
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.02.004
Abstract:
Objective:To investigate the relationship between CD24 expression and clinicopathological features in triple negative breast cancer(TNBC),and to analyze the effect of CD24 expression on epithelial mesenchymal transformation (EMT).Methods:The expression of CD24 in different breast cancer subtypes was analyzed by Gene expression Profiling Interactive Analysis database (GEPIA).Kaplan-Meier Plotter database was used to analyze the relationship between CD24 expression and related prognostic factors in breast cancer patients.Immunohistochemistry was used to detect the expression of CD24 protein in paraffin embedded tissues from 73 cases of TNBC.The relationship between CD24 expression and clinicopathological parameters was analyzed.Flow cytometry was used to separate CD24high/low cells.Transwell chamber was used to detect different migration capacities of CD24high/low,and Western blot was used to detect the relationship between CD24high/lowand changes of EMT-related proteins.Results:Compared with normal breast tissue,the expression of CD24 was significantly higher in cancer tissue,and the expression level of CD24 was the highest in TNBC tissue (P＜0.05).Compared with CD24low group,the prognosis of patients with CD24high group was worse (P＜0.05).Immunohistochemistry showed that CD24 was highly expressed in TNBC,with a positive rate of 82.19%.The expression of CD24 was not related to age,tumor size,histological grade and TNM stage (P＞0.05),but was only related to lymph node metastasis (P＜0.05).Transwell chamber results showed that the migration ability of CD24low cells was significantly weaker than that of CD24high cells (t=22.814,P＜0.05).Western blot results showed that the protein levels of E-cadherin and β-catennin in the CD24low group were significantly lower than those in the CD24high group,while the protein levels of N-cadherin and Vimentin were significantly higher than those in the CD24high group.The differences of the above indexes were statistically significant (all P＜0.05).Conclusion:CD24 is highly expressed in TNBC,EMT phenotype is associated with TNBC cells and is involved in distant metastasis,which may be a potential indicator in assessing patient prognosis.

References:

［1］SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA:A Cancer Journal for Clinicians,2021,71(1):7-33.
［2］HWANG S,PARK S,KWON Y.Recent therapeutic trends and promising targets in triple negative breast cancer［J］.Pharmacology & Therapeutics (Oxford),2019,199:30-57.
［3］ BARKAL AA,BREWER RE,MARKOVIC M,et al.CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy［J］.Nature,2019,572(7769):392-396.
［4］HAMMOND MEH.American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer ［J］.Journal of Clinical Oncology,2010,28(21):3543-3543.
［5］ DEEPAK K,VEMPATI R,NAGARAJU GP,et al.Tumor microenvironment:Challenges and opportunities in targeting metastasis of triple negative breast cancer［J］.Pharmacol Res,2020,153:104683.
［6］ REYA T,MORRISON SJ,CLARKE MF,et al.Stem cells,cancer,and cancer stem cells［J］.Nature,2001,414(6859):105-111.
［7］ BEHBOD F,ROSEN JM.Will cancer stem cells provide new therapeutic targets［J］.Carcinogenesis,2005,26(4):703-711.
［8］ DEAN M,FOJO T,BATES S.Tumour stem cells and drug resistance［J］.Nat Rev Cancer,2005,5(4):275-284.
［9］ GINESTIER C,HUR MH,CHARAFE-JAUFFRET E,et al.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome［J］.Cell Stem Cell,2007,1(5):555-567.
［10］ SHERIDAN C,JISHIMOTO H,FUCHS RK,et al.CD44+/CD24-breast cancer cells exhibit enhanced invasive properties:an early step necessary for metastasis［J］.Breast Cancer Res,2006,8(5):R59.
［11］ RICARDO S,VIEIRA AF,GERHARD R,et al.Breast cancer stem cell markers CD44,CD24 and ALDH1:expression distribution within intrinsic molecular subtype［J］.J Clin Pathol,2011,64(11):937-946.
［12］ ABRAHAM BK,FRITZ P,MCCLELLAN M,et al.Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis［J］.Clinical Cancer Research,2005,11(3):1154-1159.
［13］ MYLONA E,GIANNOPOULOU I,FASOMYTAKIS E,et al.The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas［J］.Hum Pathol,2008,39(7):1096-1102.
［14］ NI Y H,ZHAO X,WANG W.CD24,A Review of its role in tumor diagnosis,progression and therapy［J］.Curr Gene Ther,2020,20(2):109-126.
［15］ LIU G,LIU GX,FANG Y,et al.Clinicopathological and prognostic value of CD24 expression in breast cancer:a meta-analysis［J］.Int J Biol Markers,2017,32(2):e182-e189.
［16］ JANG MH,KANG HJ,JIANG KS,et al.Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer［J］.Oncology Letters,2016,12(4):2728-2733.
［17］ BAUMANN P,CREMERS N,KROESE F,et al.CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis［J］.Cancer Research,2005,65(23):10783-10793.
［18］ DENG X,APPLE S,ZHAO H,et al.CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer［J］.Oncotarget，2017,8(24):38294-38308.
［19］ WAN X,CHENG C,SHAO Q,et al.CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment［J］.Tumour Biol,2016,37(5):6073-6084.

Memo

Memo:
四川省科技厅基础科研基金资助项目（编号：2019YJ0709）；四川省中医药管理局中医药基础项目（编号：2020JC0055）；四川省南充市市校合作科研创新团队建设专项（编号：20SXCXTD0001）
Last Update: 1900-01-01